stoxline Quote Chart Rank Option Currency Glossary
  
Pacific Biosciences of California, Inc. (PACB)
2.02  -0.17 (-7.76%)    05-17 16:00
Open: 2.17
High: 2.19
Volume: 8,115,667
  
Pre. Close: 2.19
Low: 2
Market Cap: 550(M)
Technical analysis
2024-05-17 4:47:43 PM
Short term     
Mid term     
Targets 6-month :  2.86 1-year :  3.73
Resists First :  2.45 Second :  3.2
Pivot price 1.87
Supports First :  1.25 Second :  1.03
MAs MA(5) :  2.1 MA(20) :  1.76
MA(100) :  4.75 MA(250) :  8.14
MACD MACD :  -0.2 Signal :  -0.4
%K %D K(14,3) :  57.3 D(3) :  63.1
RSI RSI(14): 45.8
52-week High :  14.55 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PACB ] has closed below upper band by 31.2%. Bollinger Bands are 64% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.19 - 2.2 2.2 - 2.21
Low: 1.98 - 1.99 1.99 - 2
Close: 2 - 2.02 2.02 - 2.04
Company Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Headline News

Wed, 15 May 2024
FY2024 EPS Estimates for Pacific Biosciences of California, Inc. (NASDAQ:PACB) Lifted by Cantor Fitzgerald - MarketBeat

Wed, 15 May 2024
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.6% on Analyst Downgrade - MarketBeat

Wed, 15 May 2024
Pacific Biosciences of California (NASDAQ:PACB) Upgraded to Sell at StockNews.com - Defense World

Mon, 13 May 2024
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated - Yahoo New Zealand News

Mon, 13 May 2024
Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $2.00 at Barclays - Defense World

Fri, 10 May 2024
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 272 (M)
Shares Float 266 (M)
Held by Insiders 1.8 (%)
Held by Institutions 102 (%)
Shares Short 48,520 (K)
Shares Short P.Month 45,570 (K)
Stock Financials
EPS -1.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.61
Profit Margin -153 %
Operating Margin -142.2 %
Return on Assets (ttm) -11 %
Return on Equity (ttm) -48.6 %
Qtrly Rev. Growth 113.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.73
EBITDA (p.s.) -1.06
Qtrly Earnings Growth 0 %
Operating Cash Flow -259 (M)
Levered Free Cash Flow -307 (M)
Stock Valuations
PE Ratio -1.67
PEG Ratio 1.7
Price to Book value 0.77
Price to Sales 2.74
Price to Cash Flow -2.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android